Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: a culture and microscopic study
- PMID: 9776839
Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: a culture and microscopic study
Abstract
A systematic cultural, cytological and microscopic study of voriconazole (VCZ) and fluconazole (FCZ) damage to Cryptococcus neoformans over time was made. When haemocytometer counts were compared with colony-forming units (cfu) viability decreased with increased drug concentration and prolonged treatment time up to 48 h. Percentage viability by vital staining correlated with cfu. Concentrations of VCZ were found to be 10-fold more potent than FCZ. At 72 h, percentage viability increased in cultures with lower drug concentrations, indicating outgrowth of surviving yeast cells. Drug treatment resulted in a cytological change in a large percentage of yeast cells characterized by a large central vacuole easily observed microscopically. Vital staining showed that there was no direct relationship between cytological changes and non-viability. These novel findings add a new approach for studying the antifungal action of VCZ and FCZ against C. neoformans and provide a new perspective on their antifungal action.
Similar articles
-
Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum.Mycopathologia. 1998;142(1):3-7. doi: 10.1023/a:1006999727607. Mycopathologia. 1998. PMID: 9850592
-
Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.Chemotherapy. 2007;53(4):300-5. doi: 10.1159/000102585. Epub 2007 May 10. Chemotherapy. 2007. PMID: 17496416
-
Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole.Int J Antimicrob Agents. 2009 Jun;33(6):559-63. doi: 10.1016/j.ijantimicag.2008.11.007. Epub 2009 Feb 4. Int J Antimicrob Agents. 2009. PMID: 19195846
-
Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.Jpn J Infect Dis. 2004 Jun;57(3):113-5. Jpn J Infect Dis. 2004. PMID: 15218221
-
In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.Diagn Microbiol Infect Dis. 2004 Mar;48(3):201-5. doi: 10.1016/j.diagmicrobio.2003.09.008. Diagn Microbiol Infect Dis. 2004. PMID: 15023430
Cited by
-
Time-course proteome analysis reveals the dynamic response of Cryptococcus gattii cells to fluconazole.PLoS One. 2012;7(8):e42835. doi: 10.1371/journal.pone.0042835. Epub 2012 Aug 6. PLoS One. 2012. PMID: 22880118 Free PMC article.
-
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.Antimicrob Agents Chemother. 2009 Jan;53(1):309-11. doi: 10.1128/AAC.01216-08. Epub 2008 Oct 27. Antimicrob Agents Chemother. 2009. PMID: 18955539 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials